• / Free eNewsletters & Magazine
  • / My Account
Home>Finance>Technology>Biotechnology

Biotechnology

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Genome Editing Global Market to Grow 31.1% by 2022 - Increased R&D Expenditure in Biotechnology & Pharmaceutical Industries - Research and Markets

    Genome Editing Global Market to Grow 31.1% by 2022 - Increased R&D Expenditure in Biotechnology & Pharmaceutical Industries - Research and Markets

  2. BIO Applauds Senate Passage of Advancing Hope Act

    BIO Applauds Senate Passage of Advancing Hope Act

  3. MARKET SNAPSHOT: Clinton-Trump Debate Showdown Carries Potential To Sock Stocks

    MARKET SNAPSHOT: Clinton-Trump Debate Showdown Carries Potential To Sock Stocks

  4. UPDATE: Clinton-Trump debate showdown carries potential to sock stocks

    UPDATE: Clinton-Trump debate showdown carries potential to sock stocks

  5. PixarBio Corporation Discusses NeuroRelease™ a Non-Addictive Morphine Replacement at the 2016 NYSORA 15th Annual Symposium in New York City on September 23 - 25, 2016

    PixarBio Corporation Discusses NeuroRelease™ a Non-Addictive Morphine Replacement at the 2016 NYSORA 15th Annual Symposium in New York City on September 23 - 25, 2016

  6. Enanta Pharmaceuticals Announces Data on Eight-Week Treatment of AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Patients with Genotype 1b Chronic ...

    Enanta Pharmaceuticals Announces Data on Eight-Week Treatment of AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C

  7. Hot Topics Recap: Breast Cancer Awareness Month 2016

    Hot Topics Recap: Breast Cancer Awareness Month 2016

  8. Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1

    Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1

  9. Legal marijuana expected to pose threat to $200 billon alcohol industry

    Legal marijuana expected to pose threat to $200 billon alcohol industry

  10. UPDATE: Legal marijuana expected to pose threat to $200 billion alcohol industry

    UPDATE: Legal marijuana expected to pose threat to $200 billion alcohol industry

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.